Innovations in Pharma – Report Bundle (5 Reports)
Innovations in Pharma Bundle Report Overview
The healthcare industry constantly demands innovation, improvement, accessibility, and affordability. The ‘Innovations in Pharma’ bundle highlights the emerging drug development technologies in providing quality healthcare services.
Accessing the in-depth insight from the Innovations in Pharma bundle can help you:
- Make informed decisions about investments, partnerships, and product development
- Understand your competitors’ strengths and weaknesses, identify areas of opportunity, and develop strategies to stay ahead in the market
- Anticipate market changes and adjust your strategies accordingly
- Develop risk management strategies and ensure business continuity
Innovations in Pharma bundle is a cost-effective solution as it provides access to multiple reports at a discounted price, compared to buying individual reports:
- State of the Biopharmaceutical Industry 2023 (Single user price: $1,950)
- Immuno-Oncology (Single user price: $995)
- Microbiome-Targeting Therapeutics in Infectious Diseases (Single user price: $995)
- Neuroimmunology Drug Development (Single user price: $995)
- Gene Therapy in Oncology (Single user price: $995)
Click here to download sample pages of every report included in the Innovations in Pharma bundle
By purchasing the bundle worth $5,930 you can get access to a wealth of information and insights:
- Market Insights and Trends –It provides in-depth insights of the current and future market trends, including macroeconomic trends and M&A trends. Additionally, it helps in identifying key areas of growth as well as ‘white-space’ opportunities and strategize accordingly.
- Value Chain Analysis –It provides extensive value chain analysis comprising detailed insights across various stages of the value chain, which will help evaluation competitive positioning and identify key growth opportunities for drug discovery and development.
- Pipeline Assessment –It provides comprehensive overview of the ongoing clinical trials in the specific therapy areas which will keep an eye on the competitors new product offerings.
- Drug Development Scorecard –The scorecard helps to identify tomorrow’s leaders based on their competitive position in the most important themes impacting their industry.
We recommend this valuable source of information to anyone involved in:
- Pharmaceutical/Biopharmaceutical Manufacturers
- Clinical Research Organizations/ Contract manufacturing organizations
- Consultants
- Investment Banksand PE/VC firms
Currently working in the pharma industry or those looking to enter this market as manufacturers, suppliers, consultants, PE/VC Firms, and investment banks.
Click here to download consolidated sample pages of reports in the Innovations in Pharma bundle
Report 1: State of the Biopharmaceutical Industry 2023
The biopharmaceutical industry is considered to be highly resistant to economic downturns and financial crisis, though not completely immune to it. Inflation, drug pricing and reimbursement constraints are anticipated to significantly impact the pharmaceutical industry in 2023. Genomics, real-world evidence (RWE), and immuno-oncology (IO) are some of the emerging industry trends that are likely to have the greatest impact on the pharmaceutical industry in 2023. For instance, when combined with ongoing advances in sequencing and data analyzing technologies, genomics has the potential to improve diagnosis speed and provide opportunities to personalize patient treatment approaches.
Top Emerging Pharmaceutical Industry Trends
For more insights, Click here to download sample pages for the Innovations in Pharma Bundle
Report 2: Immuno-Oncology – Thematic Research
The field of immuno-oncology (IO) is consolidating its presence in most major types of cancer. Checkpoint modulation is the most valuable IO sector. Immuno-oncology therapeutics are transforming the treatment paradigms for patients with cancer. The development of novel drugs, biologics, and devices will lead to more effective therapies personalized to the unique immune biology within each cancer patient to stimulate and help the body’s natural defenses as a treatment for their cancer while minimizing toxicities.
Immuno-oncology Value Chain
For more insights, Click here to download sample pages for the Innovations in Pharma Bundle
Report 3: Microbiome-Targeting Therapeutics in Infectious Diseases – Thematic Research
Microbiome-targeting drugs aim to alter the microbial composition of the gut through the administration of live microbes (probiotics), or other compounds called prebiotics, to avoid administering live bacteria. Currently, only one successful microbiome-based intervention, fecal microbiota transplantation (FMT), is used in clinical practice to treat CDI. FMT involves the transfer of an entire microbial community from a healthy donor to an infected patient in order to replace the disease-associated microbiome. FMT has proven remarkable efficacy in treating CDI, which most commonly presents after antibiotic treatment. Ample opportunity remains for companies to invest in the microbiome space for a wide variety of infectious diseases indications, especially as antibiotic resistance continues to grow rapidly.
For more insights, Click here to download sample pages for the Innovations in Pharma Bundle
Report 4: Neuroimmunology Drug Development – Thematic Research
The neuroimmune system is a complex system that plays an important role in regulating nervous system health and disease. Some of the key industry trends in neuroimmunology drug development include the application of similar mechanism of action (MOA) across numerous indications as well as the development of mAbs targeting pathogenic neural proteins in Alzheimer’s disease (AD) and Parkinson’s disease (PD), among others. The majority of marketed neuroimmunology products available in the 8MM target multiple sclerosis (MS). However, there have been approvals of these products in new indications in the recent years. Big pharma companies such as Roche, Biogen, AstraZeneca, Johnson & Johnson (J&J), Novartis, Sanofi, and UCB are all involved in marketing or developing neuroimmunology products across multiple neurological indications.
Neuroimmunology Value Chain Select Key Targets and Therapy Types
For more insights, Click here to download sample pages for the Innovations in Pharma Bundle
Report 5: Gene Therapy in Oncology – Thematic Research
Gene therapies provide therapeutic benefits to patients, particularly those suffering from monogenic diseases. Gene therapies treat cancer by altering gene regulation in tumorigenic pathways and expressing genes in cells that cause them to be recognized as foreign or to elicit an immune response to tumorigenic cells. The market for gene therapies, particularly those based on viral vectors, is expected to be slowed by high therapy costs, which may limit their accessibility. Most gene therapy products for cancer are available in China followed by the five major European markets (5EU) (France, Germany, Italy, Spain, and the UK) and the US with one approved product. Existing regulatory programs facilitate the approval and development of gene therapies. However, novel reimbursement strategies are required to cover the high cost of gene therapies.
Gene Therapy Value Chain Analysis
For more insights, Click here to download sample pages for the Innovations in Pharma Bundle
Key Players
Table of Contents
Frequently Asked Questions
Genomics, real-world evidence (RWE), and immuno-oncology (IO) are some of the emerging industry trends that are likely to have the greatest impact on the pharmaceutical industry in 2023.
The key immuno-oncology market value chains are bispecific antibodies, oncolytic viruses, cell therapies, cancer vaccines, checkpoint modulators, and cytokines.
The leading companies in the microbiome-targeting therapeutics market for infectious diseases are Rebiotix Inc, Nexbiome Therapeutics, Finch Therapeutics Group Inc, Evelo Biosciences, Infant Bacterial Therapeutics AB, Osel Inc, Mikrobiomik Healthcare Company SL, and Seres Therapeutics Inc.
Some of the key industry trends in neuroimmunology drug development include the application of similar mechanism of action (MOA) across numerous indications as well as the development of mAbs targeting pathogenic neural proteins in Alzheimer’s disease (AD) and Parkinson’s disease (PD), among others.
Gene therapies provide therapeutic benefits to patients, particularly those suffering from monogenic diseases.
Get in touch to find out about our multi-purchase discounts
reportstore@globaldata.com
Tel +44 (0) 20 7947 2960
Every customer’s requirement is unique. We understand that and can customize the report basis your exact research requirements pertaining to market insights, innovation insights, strategy and planning, and competitive intelligence. You can also avail the option of purchasing stand-alone sections of the report or request for a country specific report.
Still undecided about purchasing this report?
Testimonial
“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.
GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”
“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”
Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.
Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.
Related reports
View more Pharmaceuticals reports